Dr. Takeshita is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
33 W 95th St
New York, NY 10025Phone+1 917-727-8353- Is this information wrong?
Education & Training
- Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1986 - 1988
- Yale-New Haven Medical CenterResidency, Internal Medicine, 1984 - 1986
- Yale School of MedicineClass of 1983
Certifications & Licensure
- NY State Medical License 1994 - 2026
- CT State Medical License 1986 - 1995
- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 38 citationsLenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myelomaShinsuke Iida, Takaaki Chou, Shinichiro Okamoto, Hirokazu Nagai, Kiyohiko Hatake, Hirokazu Murakami, Toshiyuki Takagi, Kazuyuki Shimizu, Henry Lau, Kenichi Takeshita, ...> ;International Journal of Hematology. 2010 Jun 18
- 205 citationsLenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's LymphomaThomas E. Witzig, Peter H. Wiernik, Timothy E. Moore, Craig B. Reeder, Craig Cole, Glen Justice, Henry G. Kaplan, Michael Voralia, Dennis Pietronigro, Kenichi Takeshit...> ;Journal of Clinical Oncology. 2009 Nov 10
- 14 citationsLenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality.Hironori Harada, Mitsumasa Watanabe, Kenshi Suzuki, Soshi Yanagita, Takahiro Suzuki, Yataro Yoshida, Akiro Kimura, Mitsuru Tsudo, Akira Matsuda, Kaoru Tohyama, Masafum...> ;International Journal of Hematology. 2009 Aug 25
- Join now to see all
Press Mentions
- AstraZeneca Enhertu Granted Priority Review in US for Metastatic HER2-Positive Solid TumoursJanuary 31st, 2024
- AstraZeneca’s Dato-DXd Significantly Improved PFS in Lung CancerJuly 3rd, 2023
- Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast CancerMarch 4th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: